December 30, 2024

web version

Penn Medicine

To: UPHS Physicians and Staff

From: **The Division of Precision and Computational Diagnostics (PCD)**
Vivianna Van Deerlin, M.D., Ph.D., Molecular Pathology Lab Director and Interim Director, PCD
Christopher Watt, M.D., Ph.D., Associate Molecular Pathology Lab Director
Alicia Carlin, Technical Manager, Molecular Pathology

Date: December 30, 2024

Re: **Temporary change to targeted IDH molecular testing**

Effective immediately, blood and bone marrow samples submitted for *IDH1/IDH2* Variant Analysis or *IDH2* Variant Analysis will be sent to Mayo Clinic Laboratories for testing due to limitations in reagent availability from the manufacturer. The only exception is standalone *IDH1* Variant Analysis for follow-up testing of patients known to have an IDH1 mutation which will continue to be tested in house. This change will be in effect until further notice.

The Mayo Clinic Laboratories *IDH* test is a highly sensitive quantitative assay for the detection of six *IDH1* R132 variants (R132H, R132S, R132C, R132G, R132P, and R132L) and ten *IDH2* variants R140 (R140Q, R140L, R140G, R140W) and R172 (R172K, R172M, R172G, R172S[G>C], R172S[G>T], R172W) seen in acute myeloid leukemia. The method is droplet digital PCR with a stated turn-around-time of 4 to 8 days. More information is available here: https://www.mayocliniclabs.com/test-catalog/overview/615859#Overview

Blood and bone marrow samples submitted for testing from the following test orders will be routed to Mayo Clinic laboratories.

- IDH1 IDH2 Variant Analysis
- IDH2 Variant Analysis

Reporting for the Mayo *IDH* test will be available under the Misc. test category. Reporting and turn-around-time for standalone *IDH1* Variant Analysis will remain

unchanged. To check on the status of an order contact client services (1-800-PENNLAB).

Please contact the Molecular Pathology Laboratory at 215-615-3094 with any questions.